Service de neurologie, CHU de Saint-Étienne, 42055 Saint-Étienne cedex, France; Inserm CNRS, laboratoire SynAtac, MeliS, université Jean-Monnet, Saint-Étienne, France.
Rev Neurol (Paris). 2024 Nov;180(9):876-887. doi: 10.1016/j.neurol.2024.09.002. Epub 2024 Sep 24.
Over the past 30 years, about 20 antibodies have been identified in immune-mediated neuropathies, recognizing membrane or intracellular proteins or glycolipids of neuron and Schwann cells. This article reviews the different methods used for their detection, what we know about their pathogenic role, how they have helped identify several disorders, and how they are essential for diagnosis. Despite sustained efforts, some immune-mediated disorders still lack identified autoantibodies, notably the classical form of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The reasons for this are discussed. The article also tries to determine potential future developments in antibody research, particularly the use of omic approaches and the search for other types of biomarkers beyond diagnostic ones, such as those that can identify patients who will respond to a given treatment.
在过去的 30 年中,已经在免疫介导性神经病中鉴定出了约 20 种抗体,这些抗体识别神经元和雪旺细胞的膜或细胞内蛋白或糖脂。本文综述了用于检测这些抗体的不同方法、它们的致病作用、如何帮助鉴定几种疾病以及它们对诊断的重要性。尽管做出了持续的努力,但一些免疫介导性疾病仍然缺乏已鉴定的自身抗体,尤其是经典型吉兰-巴雷综合征和慢性炎症性脱髓鞘性多发性神经病。本文讨论了造成这种情况的原因。本文还试图确定抗体研究的潜在未来发展方向,特别是使用组学方法以及寻找除诊断标志物以外的其他类型的生物标志物,例如那些可以识别对特定治疗有反应的患者的生物标志物。